Literature DB >> 334216

Kinetic interaction of nomifensine with a 1, 5-benzodiazepine (clobazam).

W Rupp, W Heptner, M Uihlein, R Bender, K Taeuber.   

Abstract

1. Among the numerous possibilities of drug interactions, pharmacokinetic interactions may cause mutual changes in absorption, distribution, metabolism and elimination of either drug. In the present study this approach was used to investigate pertinent effects of nomifensine and clobazam. 2. Ten normal subjects participated in an intra-individual comparison of nomifensin 75 mg alone and in combination with clobazam 15 and 30 mg. The study design was carried out according to a Latin square in double-blind conditions. One-week wash-out periods were used between the trial days. Serum levels of nomifensine were measured by radioimmunoassay (RIA) and of original clobazam by gas chromatography (GC). Classical criteria for bioavailability (peak serum levels, time of peak, area under the serum level time curve) and the half-life of elimination from the serum were used for retrieval of pharmacokinetic information. 3. Results showed no relevant differences in the criteria mentioned above, after administration of each drug alone or in combination. Therefore, extrapolations were made to multiple dose kinetics based on assumptions derived from practical therapy. They showed comprehensive agreement with therapeutic results in depressed patients. 4. The use of the classical criteria for bioavailability, in addition to the calculation of the half-time of elimination from serum, provides sufficient information for the decision whether pharmacokinetic drug interaction is present or absent. There was no such interaction after single doses of nomifensine or clobazam.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 334216      PMCID: PMC1429110          DOI: 10.1111/j.1365-2125.1977.tb05741.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  3 in total

1.  The significance of drug interactions in the evaluation of psychotropic drugs.

Authors:  R A Braithwaite
Journal:  Br J Clin Pharmacol       Date:  1976-02       Impact factor: 4.335

Review 2.  Pharmacokinetic drug interactions. Sedative, hypnotic, and antianxiety agents.

Authors:  M E Kosman
Journal:  JAMA       Date:  1974-09-09       Impact factor: 56.272

3.  Pharmacokinetic drug interactions.

Authors:  L F Prescott
Journal:  Lancet       Date:  1969-12-06       Impact factor: 79.321

  3 in total
  7 in total

1.  [Analytical data of the new 1,5-benzodiazepine clobazam (Frisium) and its main metabolite nor-clobazam (author's transl)].

Authors:  H Schütz
Journal:  Arch Toxicol       Date:  1978-12-28       Impact factor: 5.153

2.  Pharmacokinetics of single and multiple doses of clobazam in humans.

Authors:  W Rupp; M Badian; O Christ; P Hajdú; R D Kulkarni; K Taeuber; M Uihlein; R Bender; O Vanderbeke
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

Review 3.  Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies.

Authors:  Jose de Leon; Edoardo Spina; Francisco J Diaz
Journal:  Ther Drug Monit       Date:  2013-02       Impact factor: 3.681

4.  Pharmacokinetics of nomifensine in impaired renal function.

Authors:  S Ringoir; N Lameire; M Munche; W Heptner; K Taeuber
Journal:  Br J Clin Pharmacol       Date:  1977       Impact factor: 4.335

5.  Acute effects of amitriptyline on human performance and interactions with diazepam.

Authors:  A Patat; M J Klein; M Hucher; J Granier
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Nomifensine: A review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-07       Impact factor: 9.546

Review 7.  Clobazam: a review of its pharmacological properties and therapeutic use in anxiety.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-09       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.